Avidity Biosciences released promising early and midstage Phase I/II data for del-zota, an antibody-oligonucleotide conjugate targeting Duchenne muscular dystrophy. Treated patients showed reversal of disease progression after continuous therapy for one year, alongside functional improvements. Concurrently, Avidity executed the second-largest follow-on public offering of 2025, pricing 15 million shares at $40 each, raising capital to advance this and other pipeline assets.